Anti-Hu CD266 Purified

*Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan;2 (1) :103-108, URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=yoriki+r+akashi+s , *Sanz AB, Sanchez-Niñ o MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A: Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells. PLoS One. 2012;7 (10) :e47440., URL: http://www.ncbi.nlm.nih.gov/pubmed/23077618 , *Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2003 Jan 1;170 (1) :341-8., URL: http://www.ncbi.nlm.nih.gov/pubmed/12496418 , *Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H: Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol. 2010 Aug 1;185 (3) :1593-605. , URL: http://www.ncbi.nlm.nih.gov/pubmed/20610643

The mouse monoclonal antibody ITEM-4 recognizes an extracellular epitope of CD266 / TWEAK R, a TNFR superfamily receptor for CD255 / TWEAK, a TNF-like weak inducer of apoptosis.